AB
DNA icon

Amalgamated Bank’s Ginkgo Bioworks DNA Stock Holding History

Amalgamated Bank’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,298
Closed -$11K – 1958
2025
Q4 		$11K Sell
1,298
-30
-2% -$323 ﹤0.01% 2370
2025
Q3 		$19K Hold
1,328
– – ﹤0.01% 2143
2025
Q2 		$15K Buy
+1,328
New +$10.3K ﹤0.01% 2233
2024
Q2 		– Sell
-2,238
Closed -$104K – 3040
2024
Q1 		$104K Sell
2,238
-3,510
-61% -$182K ﹤0.01% 1715
2023
Q4 		$389K Sell
5,748
-359
-6% -$22K ﹤0.01% 1536
2023
Q3 		$442K Buy
6,107
+824
+16% +$65.9K ﹤0.01% 1471
2023
Q2 		$393K Buy
5,283
+1,441
+38% +$85.3K ﹤0.01% 1552
2023
Q1 		$204K Sell
3,842
-401
-9% -$25.4K ﹤0.01% 1797
2022
Q4 		$287K Buy
4,243
+340
+9% +$31.3K ﹤0.01% 1716
2022
Q3 		$487K Buy
3,903
+34
+0.9% +$4.05K ﹤0.01% 1447
2022
Q2 		$368K Buy
+3,869
New +$472K ﹤0.01% 1620

Other funds holding DNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Bank's DNA Position: Q1 2026 in Review

Amalgamated Bank sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 1,298 shares — an estimated $11K sold.

Amalgamated Bank first reported a position in DNA in Q2 2022 and held it in 11 quarters. The position peaked at $487K in Q3 2022. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Amalgamated Bank reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,298 Ginkgo Bioworks shares in Q1 2026, an estimated $11K.
  • Amalgamated Bank first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 11 quarters.
  • Amalgamated Bank's Ginkgo Bioworks position peaked at $487K in Q3 2022.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.